세계의 환자 유래 이종이식편/PDX 모델 시장 : 유형, 종양 유형, 용도, 최종 사용자별 예측(2025-2030년)

The Patient-Derived Xenograft/PDX Model Market was valued at USD 326.36 million in 2023, expected to reach USD 365.24 million in 2024, and is projected to grow at a CAGR of 12.27%, to USD 734.07 million by 2030.

Patient-Derived Xenograft (PDX) models are indispensable tools in cancer research, representing a crucial bridge between in vitro studies and clinical applications. These models involve transplanting human tumor tissues into immunocompromised mice, thus maintaining the genetic heterogeneity of the patient's tumor. This fidelity makes PDX models invaluable for preclinical testing and accelerating personalized medicine initiatives. The necessity of PDX models lies in their ability to provide more accurate predictions of treatment efficacy, thereby aiding drug development and overcoming the limitations of traditional cell line models. They are primarily applied in oncology, supporting the screening of anti-cancer drugs and the development of biologics. The primary end-users include research institutions, pharmaceutical companies, and contract research organizations (CROs).

The market for PDX models is driven by the increasing prevalence of cancer, a robust pipeline of oncology drugs, and the growing emphasis on precision medicine. Technological advancements in gene editing and sequencing are also significantly propelling market growth. Emerging opportunities include the integration of artificial intelligence for data analysis and the development of 3D PDX models, which offer enhanced tumor microenvironment simulation. Companies can capitalize on these opportunities by investing in these areas to enhance model accuracy and predictability. However, challenges such as high costs of model development, ethical concerns regarding animal use, and limited accessibility for small biotechs may impede market growth.

To spur innovation, research should focus on optimizing the development process to reduce costs, increasing model diversity to cover rare cancer types, and advancing the co-clinical trial design to better correlate PDX findings with patient outcomes. Increasing collaborations between academic institutions and industry can also expedite innovation. The PDX model market is highly dynamic, characterized by continuous technological advances and a competitive landscape marked by strategic partnerships and acquisitions aimed at expanding service portfolios and geographical reach.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Patient-Derived Xenograft/PDX Model Market

The Patient-Derived Xenograft/PDX Model Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing demand for personalized medicine
  • Oncology and preclinical development
  • Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
• Market Restraints
  • High cost of personalized PDX model
• Market Opportunities
  • Rising demand for humanized PDX Model
  • Growth in pharma R&D
• Market Challenges
  • Stringent guidelines regarding the ethical use of animals in cancer research

Porter's Five Forces: A Strategic Tool for Navigating the Patient-Derived Xenograft/PDX Model Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Patient-Derived Xenograft/PDX Model Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Patient-Derived Xenograft/PDX Model Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Patient-Derived Xenograft/PDX Model Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Patient-Derived Xenograft/PDX Model Market

A detailed market share analysis in the Patient-Derived Xenograft/PDX Model Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Patient-Derived Xenograft/PDX Model Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Patient-Derived Xenograft/PDX Model Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Patient-Derived Xenograft/PDX Model Market

A strategic analysis of the Patient-Derived Xenograft/PDX Model Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., BioDuro LLC, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera BioLabs Inc., Inotiv, Inc. by Bioanalytical Systems, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Oncodesign Services, Pharmatest Services LLC by ValiRx Finland Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and XENTECH TECHNOLOGIES PRIVATE LIMITED.

Market Segmentation & Coverage

This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Mice Models and Rat Models.
• Based on Tumor Type, market is studied across Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models, Respiratory Tumor Models, and Urological Tumor Models.
• Based on Application, market is studied across Basic Cancer Research, Biomarker Analysis, and Preclinical Drug Development.
• Based on End-User, market is studied across Academic & Research Institutions, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for personalized medicine
    • 5.1.1.2. Oncology and preclinical development
    • 5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of personalized PDX model
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising demand for humanized PDX Model
    • 5.1.3.2. Growth in pharma R&D
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Extensive use of mouse models in oncology to develop novel therapeutics
  • 5.2.2. Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
  • 5.2.3. Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
  • 5.2.4. End-User: Rising applicability of patient-derived xenografts in academic and research institutes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Patient-Derived Xenograft/PDX Model Market, by Type

• 6.1. Introduction
• 6.2. Mice Models
• 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

• 7.1. Introduction
• 7.2. Gastrointestinal Tumor Models
• 7.3. Gynecological Tumor Models
• 7.4. Hematological Tumor Models
• 7.5. Respiratory Tumor Models
• 7.6. Urological Tumor Models

8. Patient-Derived Xenograft/PDX Model Market, by Application

• 8.1. Introduction
• 8.2. Basic Cancer Research
• 8.3. Biomarker Analysis
• 8.4. Preclinical Drug Development

9. Patient-Derived Xenograft/PDX Model Market, by End-User

• 9.1. Introduction
• 9.2. Academic & Research Institutions
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Patient-Derived Xenograft/PDX Model Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Invivo Biosystems and Bioreperia Partner to Enhance Cancer Drug Testing with Advanced PDX Models
  • 13.3.2. Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec's 3D Spheroid Screening Platform, Kiya-Predict
  • 13.3.3. Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abnova Corporation
• 2. Altogen Labs
• 3. Aragen Life Sciences Pvt. Ltd.
• 4. BioDuro LLC
• 5. BioReperia AB
• 6. Champions Oncology, Inc.
• 7. Creative Biolabs
• 8. Crown Bioscience by JSR Corporation
• 9. EPO Berlin-Buch GmbH
• 10. GemPhamatech LLC
• 11. Hera BioLabs Inc.
• 12. Inotiv, Inc. by Bioanalytical Systems, Inc.
• 13. InSphero AG
• 14. LIDE Shanghai Biotech, Ltd.
• 15. Oncodesign Services
• 16. Pharmatest Services LLC by ValiRx Finland Oy
• 17. TheraIndx Lifesciences Pvt. Ltd.
• 18. Urosphere SAS
• 19. WuXi AppTec Co., Ltd.
• 20. XENTECH TECHNOLOGIES PRIVATE LIMITED